Proteins behaving badly: Emerging technologies in profiling biopharmaceutical aggregation

Zahra Hamrang, Nicholas J W Rattray, Alain Pluen

    Research output: Contribution to journalArticlepeer-review


    Over recent decades biotechnology has made significant advances owing to the emergence of powerful biochemical and biophysical instrumentation. The development of such technologies has enabled high-throughput assessment of compounds, the implementation of recombinant DNA technology, and large-scale manufacture of monoclonal antibodies. Such innovations have ultimately resulted in the current experienced biopharmaceutical stronghold in the therapeutic market. Yet aggregate prediction and profiling remains a challenge in the formulation of biopharmaceuticals due to artifacts associated with each analytical method. We review some emerging trends and novel technologies that offer a promising potential for accurately predicting and profiling protein aggregation at various stages of biopharmaceutical product design. © 2013 Elsevier Ltd.
    Original languageEnglish
    Pages (from-to)448-458
    Number of pages10
    JournalTrends in Biotechnology
    Issue number8
    Publication statusPublished - Aug 2013


    • Aggregation
    • Biopharmaceuticals
    • Manufacture
    • Product development
    • Quality by design


    Dive into the research topics of 'Proteins behaving badly: Emerging technologies in profiling biopharmaceutical aggregation'. Together they form a unique fingerprint.

    Cite this